HIV-1 CRF63_02A6 models as a tool for evaluating efficacy of developing antiretroviral drugs

Highly active antiretroviral therapy (HAART) allows not only to control the infection process in certain patient, but also to reduce a risk of HIV infection spreading in general, so that one of the goals for international community fighting against HIV-spread is to maximize coverage of infected subj...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	D. P. Zyryanova, N. V. Bogacheva, A. V. Totmenin, N. M. Gashnikova
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2020
Materias:	model of the hiv-1 crf63 02a6hiv-1 hiv-1 infectious isolates hiv-1 infectious molecular clones antiretroviral therapy Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/23151705d5eb4e78a9c95be0ce0ae772
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:23151705d5eb4e78a9c95be0ce0ae772
record_format	dspace
spelling	oai:doaj.org-article:23151705d5eb4e78a9c95be0ce0ae7722021-11-22T07:09:55ZHIV-1 CRF63_02A6 models as a tool for evaluating efficacy of developing antiretroviral drugs2220-76192313-739810.15789/2220-7619-MHC-1261https://doaj.org/article/23151705d5eb4e78a9c95be0ce0ae7722020-11-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1261https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Highly active antiretroviral therapy (HAART) allows not only to control the infection process in certain patient, but also to reduce a risk of HIV infection spreading in general, so that one of the goals for international community fighting against HIV-spread is to maximize coverage of infected subjects with HAART. Antiretroviral therapy in HIV infection is administered lifelong, so that therapeutic efficacy may be lowered due to emergence of resistant HIV-1 variants. Currently, development of new antiretroviral drugs is currently underway throughout the world, therefore standard HIV-1 models are demanded to evaluate antiviral efficacy of promising drugs. To reliably assess drug efficiency regarding Russiawide HIV-1 variants, HIV-1 genovariants widespread in Russia should be used as a virus model. A recently emerged recombinant form of CRF63_02A6 HIV-1 is spread in Russia being currently a dominant variant detected among HIV-infected individuals in an extended region of the Siberian Federal District: in the Novosibirsk, Tomsk, Omsk, Kemerovo Regions, Krasnoyarsk and Altai Krai. We have obtained CRF63_02A6 infectious isolates of HIV-1, one of which contains mutations, reducing the sensitivity to the applied inhibitors of the virus reverse transcriptase. In addition, we constructed infectious molecular clones based on HIV-1 CRF63_02A6 variants with an affinity for CCR5 coreceptors and CXCR4. Infectious isolates and molecular clones CRF63_02A6 tested as models for assessing efficacy of antiretroviral drugs using the example of the drug “Efavirenz”. The fifty percent inhibitory concentration determined on the models of HIV-1 infectious molecular clones and HIV-1 isolate 18RU7056 ranged from 0.00027 pg/ml to 0.00046 pg/ml being in agreement with data published elsewhere. Concentrations of “Efavirenz” used in the study did not suppress the replication of HIV-1 12RU6987, which is resistant to non-nucleoside reverse transcriptase inhibitors, which confirms the decrease in the sensitivity of HIV-1 12RU6987 to “Efavirenz” by no less than 10,000 times. Thus, our data demonstrate that CRF63_02A6 HIV-1 isolated strains and infectious molecular clones are relevant and complementary tools for assessing efficacy of developing drugs aimed at suppressing HIV-1, including non-nucleoside-resistant virus reverse transcriptase inhibitors.D. P. ZyryanovaN. V. BogachevaA. V. TotmeninN. M. GashnikovaSankt-Peterburg : NIIÈM imeni Pasteraarticlemodel of the hiv-1crf63 02a6hiv-1hiv-1 infectious isolateshiv-1 infectious molecular clonesantiretroviral therapyInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 10, Iss 4, Pp 769-774 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	model of the hiv-1 crf63 02a6hiv-1 hiv-1 infectious isolates hiv-1 infectious molecular clones antiretroviral therapy Infectious and parasitic diseases RC109-216
spellingShingle	model of the hiv-1 crf63 02a6hiv-1 hiv-1 infectious isolates hiv-1 infectious molecular clones antiretroviral therapy Infectious and parasitic diseases RC109-216 D. P. Zyryanova N. V. Bogacheva A. V. Totmenin N. M. Gashnikova HIV-1 CRF63_02A6 models as a tool for evaluating efficacy of developing antiretroviral drugs
description	Highly active antiretroviral therapy (HAART) allows not only to control the infection process in certain patient, but also to reduce a risk of HIV infection spreading in general, so that one of the goals for international community fighting against HIV-spread is to maximize coverage of infected subjects with HAART. Antiretroviral therapy in HIV infection is administered lifelong, so that therapeutic efficacy may be lowered due to emergence of resistant HIV-1 variants. Currently, development of new antiretroviral drugs is currently underway throughout the world, therefore standard HIV-1 models are demanded to evaluate antiviral efficacy of promising drugs. To reliably assess drug efficiency regarding Russiawide HIV-1 variants, HIV-1 genovariants widespread in Russia should be used as a virus model. A recently emerged recombinant form of CRF63_02A6 HIV-1 is spread in Russia being currently a dominant variant detected among HIV-infected individuals in an extended region of the Siberian Federal District: in the Novosibirsk, Tomsk, Omsk, Kemerovo Regions, Krasnoyarsk and Altai Krai. We have obtained CRF63_02A6 infectious isolates of HIV-1, one of which contains mutations, reducing the sensitivity to the applied inhibitors of the virus reverse transcriptase. In addition, we constructed infectious molecular clones based on HIV-1 CRF63_02A6 variants with an affinity for CCR5 coreceptors and CXCR4. Infectious isolates and molecular clones CRF63_02A6 tested as models for assessing efficacy of antiretroviral drugs using the example of the drug “Efavirenz”. The fifty percent inhibitory concentration determined on the models of HIV-1 infectious molecular clones and HIV-1 isolate 18RU7056 ranged from 0.00027 pg/ml to 0.00046 pg/ml being in agreement with data published elsewhere. Concentrations of “Efavirenz” used in the study did not suppress the replication of HIV-1 12RU6987, which is resistant to non-nucleoside reverse transcriptase inhibitors, which confirms the decrease in the sensitivity of HIV-1 12RU6987 to “Efavirenz” by no less than 10,000 times. Thus, our data demonstrate that CRF63_02A6 HIV-1 isolated strains and infectious molecular clones are relevant and complementary tools for assessing efficacy of developing drugs aimed at suppressing HIV-1, including non-nucleoside-resistant virus reverse transcriptase inhibitors.
format	article
author	D. P. Zyryanova N. V. Bogacheva A. V. Totmenin N. M. Gashnikova
author_facet	D. P. Zyryanova N. V. Bogacheva A. V. Totmenin N. M. Gashnikova
author_sort	D. P. Zyryanova
title	HIV-1 CRF63_02A6 models as a tool for evaluating efficacy of developing antiretroviral drugs
title_short	HIV-1 CRF63_02A6 models as a tool for evaluating efficacy of developing antiretroviral drugs
title_full	HIV-1 CRF63_02A6 models as a tool for evaluating efficacy of developing antiretroviral drugs
title_fullStr	HIV-1 CRF63_02A6 models as a tool for evaluating efficacy of developing antiretroviral drugs
title_full_unstemmed	HIV-1 CRF63_02A6 models as a tool for evaluating efficacy of developing antiretroviral drugs
title_sort	hiv-1 crf63_02a6 models as a tool for evaluating efficacy of developing antiretroviral drugs
publisher	Sankt-Peterburg : NIIÈM imeni Pastera
publishDate	2020
url	https://doaj.org/article/23151705d5eb4e78a9c95be0ce0ae772
work_keys_str_mv	AT dpzyryanova hiv1crf6302a6modelsasatoolforevaluatingefficacyofdevelopingantiretroviraldrugs AT nvbogacheva hiv1crf6302a6modelsasatoolforevaluatingefficacyofdevelopingantiretroviraldrugs AT avtotmenin hiv1crf6302a6modelsasatoolforevaluatingefficacyofdevelopingantiretroviraldrugs AT nmgashnikova hiv1crf6302a6modelsasatoolforevaluatingefficacyofdevelopingantiretroviraldrugs
_version_	1718417904402169856

HIV-1 CRF63_02A6 models as a tool for evaluating efficacy of developing antiretroviral drugs

Ejemplares similares